A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

It’s the first FDA approval for a pain medication in 25 years. How does the drug work, and who is it for?

Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

A generation has passed since the peak in AIDS-related deaths. Few people under 30 years old understand what AIDS does to the ...

The foundation of patient-focused drug development (PFDD) is to involve patients in the entire drug development process, from clinical trial design to post-market surveillance. While traditional ...